Knowde Enhanced TDS
Identification & Functionality
- INCI Name
- Ingredient Origin
- Cosmetic Ingredients Functions
- Technologies
Features & Benefits
- Benefit Claims
Applications & Uses
- Markets
- Use Level
- 0.5%
- Application pH Range
- 5.8 – 7.0
- Mode of Action
Imbalanced immune responsiveness can trigger chronic inflammation in the skin. In this condition distinct proinflammatory mediators, like interleukin-8 (IL-8), are overexpressed, leading to persistance of an inflamed status in involved cells. The anti-inflammatory activity of Modukine could be confirmed both in lymphocytes isolated from blood of 5 atopic eczema patients and in human keratinocytes. Inflammatory responses in these cell types were induced by addition of Tumor Necrosis Factor-α (TNF-α). Modukine was shown to reduce significantly the IL-8 expression in both cases.
Hyperproliferation is another sign of inflammation. Proliferation in TNF-α treated keratinocytes was normalized by Modukine, with the result of a balanced epidermal differentiation enabling the induction of lipid barrier repair in the stratum corneum.
Due to its regulatory influence on imbalanced cell responses Modukine can be classified as a biological cell response modifier. The in vitro results could be confirmed by in vivo studies on humans.In a pilot study conducted on 5 volunteers with healthy skin local inflammation was created by applying histamine after the skin had been slightly scratched. Compared with controls, an O/W cream with 0.5 % Modukine was shown to accelerate reduction of skin itching and redness.
Another study was conducted on 20 human volunteers suffering from extremely dry, seborrhoic skin. Daily application of an O/W cream with 0.5 % Modukine over a period of 4 weeks led to a 50 % reduction of transepidermal water-loss (TEWL). The values measured reached those of normal skin. At the same time, an increase in skin moisture was found. The improved skin condition was also characterized by a significant reduction of skin roughness.
- Applications
Modukine is recommended for preventive and accompanying care in the treatment of problematic, extremely dry or atopic dry skin conditions.
- Processing
Short heating of a Modukine-containing solution to approx. 40 °C does not affect the bioactivity of this material. Avoid alkaline pH values.
Properties
- Odor
- Odorless
- Soluble in
- Water
Regulatory & Compliance
- Certifications & Compliance
Technical Details & Test Data
- Product Solubility
Optimum solubility of Modukine is reached in the pH range 6 to 7, for example in di-Na-Citrate/NaOH buffer according to Soerensen: 0.1 mol di-Na-Citrate + 0.1 mol NaOH; mixed 1:1, pH 6.6.The resultant buffer solution with Modukine is opaque.
Safety & Health
- Physiological Safety
Acute oral toxicity
Modukine was not tested on rats because this material is derived exclusively from milk.
Eye Irritation Test
Modukine, used at 1 % in citrate buffer pH 6, was tested on the chorioallantoic embrane of the hen’s egg where it produced an irritation index of 0.06 and was classified as “non-irritant”.
Skin compatibility
Human Repeated Insult Patch Test (RIPT according to Shelanski):
An O/W cream containing 1 % Modukine was tested on 50 volunteers with sensitive skin (among them 10 eczema patients) over a period of 5 weeks. None of the volunteers was found to produce any skin reaction; therefore, the test product could be classified as harmless”. In addition, this testing model did not produce any signs of sensitization. For this reason, the study conducted would support to label the test product as hypoallergenic”.
Packaging & Availability
- Packaging Information
- Available pack sizes: 0.1 kg; 0.5 kg; 1 kg; 5 kg
- Sample size: 5 g
Storage & Handling
- Storage and Handling
If kept in tightly sealed containers at temperatures between 10 °C and 25 °C, Modukine has a shelf life of at least 2 years.
- Preservative System
- Phenoxyethanol
- Sodium dehydroacetate